Navigation Links
Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share
Date:11/10/2009

- 11.7% Special Items ($31) ($48) ($722) ($94) Operating Income Before Special Items $257 $251 2% $955 $1,000 (5%) Operating Margin Before Special Items 14.3% 12.7% 13.6% 12.9%

Revenue of $1.8 billion declined 9% in the quarter with an organic revenue decline of 5% and a 4% decline due to changes in foreign currency. ADT's recurring revenue grew 4% organically on a global basis. Systems installation and service revenue declined 14% organically, mostly due to weakness in North America and Europe, as a result of continuing lower sales to commercial customers, including the retailer end market.

Operating income was $226 million in the quarter and the operating margin was 12.6%. Special items of $31 million resulted primarily from restructuring activities. Operating income before special items of $257 million increased $6 million despite a $7 million negative impact from foreign currency. The operating margin before special items improved 160 basis points to 14.3%, as cost-containment initiatives, restructuring activities and growth in ADT's higher-margin recurring revenue business more than offset volume declines.

Full year revenue of $7.0 billion decreased 9% with an organic revenue decline of 4%. Operating income was $233 million and included $722 million of special items. Operating income before special items of $955 million decreased $45 million driven by a negative foreign currency impact of $56 million. The operating margin before special items improved 70 basis points to 13.6%.

Flow Control

                            Q4 2009  Q4 2008 % Change FY 2009 FY 2008 % Change
                            -------  ------- -------- ------- ------- --------
    Revenue                 $1,010   $1,188     (15%) $3,850  $4,418   (13%)
     Operating Income         $126     $152     (
'/>"/>
SOURCE Tyco International Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research
2. Tyco International to Present at the Citi Industrial Manufacturing & Transportation Conference
3. AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation
4. HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China
5. Allied Worlds Nicole Baummer and Marjorie Thompson to Speak at PLUS International Conference
6. Service Corporation International Announces Third Quarter 2009 Financial Results
7. Stenum Hospital Kicks off International Rollout of M6 Artificial Lumbar Disc Replacement Surgery
8. FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDAs international posts, LASIK eye surgery, and FDA MedWatch safety alerts
9. Service Corporation International Announces Schedule for Its Third Quarter 2009 Earnings Release and Conference Call
10. Blue Cross and Blue Shield of Floridas Power of the Human Voice Campaign Wins Prestigious DMA International ECHO Gold Award
11. MediSend International Joins the Clinton Global Initiative With the Afghanistan Health and Human Resource Initiative

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...l, November 20 Cardio Va....CVSLMEDICAL.COM , a leading,developer of advanced...d that,the company,s Board of Directors has decide...a and the Far East for its proprietary next-genera...oplasty (PCTA) procedures. , Cardio Vascu...
(Date:11/20/2009)...o formaldehyde used for embalming in the funeral i...death from myeloid leukemia, according to a new st...f the National Cancer Institute . , Previous stu...poietic malignancies and brain cancer in anatomist... of whom may have worked with formaldehyde. , ...
(Date:11/20/2009)... buying 90-day supply, study finds , , F...month supply of prescription drugs is up to one-th...ing to a new study. , U.S. researchers analyzed... 2000 and 2005, and found that patients who bought...y saved an average 29 percent in out-of-pocket cos...
(Date:11/20/2009)...ov. 20 Missouri state employees in...will now have the option to choose Mercy Health Pl... Missouri Consolidated Health Care Plan (MCHCP) an...h Central Missouri regions include the following c...llas, Douglas, Greene, Hickory, Howell, Jasper, La...
(Date:11/20/2009)... The Senate,s newly rel...Affordable Care Act") infringes on Americans, heal... Blevins, president of the Institute for Health Fr...ton, D.C. ,, The bill would (among many other ...ident to buy government-sanctioned health insuranc...
Breaking Medicine News(10 mins):Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2Health News:Three-Month Supply Lowers Drug Costs 2Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:Senate Mandatory Health-Insurance Bill Infringes on Choice and Privacy 2
...h, scientists have successfully converted human em...ope that in future, replacement cartilage could be...s and medical // problems, including sports injuri...rnal Tissue Engineering, involved growing human em...
...s are developing tests that can identify the begin...l signs of the disease emerge. The researche...at the annual meeting of the Society for Neuroscie... study groups, doctors could start using the tests...
...hat replaces some carbohydrates with either protei...blood pressure and cholesterol levels, resulting i... disease, // according to government-funded studie...otein-rich food, mostly from plant sources, or to ...
...t heart disease is ranked as the first most common... test called dobutamine stress echocardiography th...s in women. // The study has been conducted ...that can be categorized into two- traditional and ...
...be now detected by using a hand-held scope called ...Agency from the fund given by National Institute o... blue light that // is better than the conventiona... is achieved when oral cancer is treated in its ea...
...is patients in Britain can look forward to some re...vailable to them for the first time, following app...m Canada. // Patients in Britain will soon b...s yet to be licensed in the UK. The Home Office ha...
Other Medicine News:Health News:Another Potential Of Stem Cells Discovered: Used For Growing Cartilage 2Health News:Diagnosis of Alzheimer's years before clinical signs emerge 2Health News:A new study by John Hopkins University proposes formula for good health 2Health News:A new study by John Hopkins University proposes formula for good health 3Health News:A Simple Test To Detect Heart Disease In Women Can Be Lifesaving 2Health News:Relief For British MS Patients: Cannabis-Based Oral Spray 2
(Date:11/20/2009)...Newswire-FirstCall/ -- Smith & Nephew ( SNN, L...ce the signing of a technology development contrac...t may lead to the creation of a fracture fixation ...the limbs of soldiers who sustain battlefield inju...ch Projects Agency (DARPA), the central research a...
(Date:11/19/2009)... BioCryst Pharmaceuticals...g of a public offering of 5,000,000 shares of its ...s proceeds of $48.75 million. All of the shares a...ive shelf registration statement previously filed ...ryst has also granted the underwriters a 30-day op...
(Date:11/19/2009)...9 /PRNewswire-Asia/ -- ScinoPharm, a leading globa...PIs), announced that its,Tainan facility has recei...SafeBridge(R) Consultants, Inc. The Certification ...n the safe handling of potent active,pharmaceutica...ratories and,production areas used for the manufac...
Breaking Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2CQ Forum on Biosimilar Biological Products Wed June 17 2009 12618 1Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 1Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 2Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 3Coming Soon 3A Lung Cancer Spray 3F 48863 1Coming Soon 3A Lung Cancer Spray 3F 48863 2
...in Long-term PASI 75, Response and Marked Improve... Study Findings, BUENOS AI...s from an international, Phase 3 study showed that... severe plaque psoriasis receiving,two doses of us...nt,reduction in psoriasis at week 12, the primary ...
...es, Inc. (Nasdaq: RMTI ), a leading, innovative m...ialty pharmaceuticals focused on the end-,stage-re... has begun dosing,patients in its Phase IIb Dose-R...hate (SFP), the Company,s physiological iron-maint...n is a double-blind, multi-center,randomized, plac...
Other Medicine Technology:Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 2Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 3Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 4Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 5Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 6Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 2Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 3Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 4
VACUETTE® Tube Holders
Safety Phlebotomy PROGUARD II Safety Needle Holder
Optima III 45 Noninsulated Duck-Bill Grasper, without ratchet
Optima III Noninsulated Stabilizing Grasper, with ratchet
Medicine Products: